

Index

Note: Page numbers of article titles are in **boldface** type.

A

Abortion

surgical

IUD insertion after, **583–591** (See also Intrauterine device (IUD) insertion)

ACA. See Affordable Care Act (ACA)

Adolescent(s)

cognitive development in, 632

contraception for, **631–645**

access to, 638–639

barrier methods, 637

CHC, 636–637

contraceptive patch, 637

contraceptive ring, 637

copper IUD, 634–635

discussion during reproductive health visit, 633

ENG implant, 634

introduction, 631–632

IUDs

special considerations for, 635

LARC methods, 633

LNG IUDs, 634

options, 633–637

POPs, 636

postpregnancy insertion, 635

progestin-only methods, 636

successful programs for, 639

high-risk behavior among, 632

OTC access to OCs by, 623–624

PID testing in, 635

pregnancy in

costs related to, 631–632

prevalence of, 631–632

reproductive health education for, 638

STI testing in, 635

Adolescent health, 632

Adolescent reproductive health visit, 632–633

Affordable Care Act (ACA)

contraceptive coverage and, **605–617**

discussion, 613–614

contraceptive coverage mandate, 607–614 (See also Contraceptive coverage mandate, of ACA)

described, 605–607

Affordable (*continued*)

- in family planning, 607
- implementation of
 - challenges related to, 610–611
 - legal challenges to, 609–610
 - in Medicaid expansion, 607
 - in preventive health care, 605–607

Antibiotic(s)

- before immediate IUD insertion after surgical abortion, 585

Antidiuretics

- for unscheduled bleeding associated with copper IUD, 596

Antifibrinolytic agents

- for unscheduled bleeding associated with copper IUD, 596
- for unscheduled bleeding associated with LNG IUD, 597

Antiprogestins

- for unscheduled bleeding associated with ENG implant, 600
- for unscheduled bleeding associated with LNG IUD, 598

B

Barrier methods

- in adolescent contraception, 637

Bleeding

- COCs and, 674–675

unscheduled

LARC-related

- therapeutic options for, **593–603** (*See also* Long-acting reversible contraception (LARC), unscheduled bleeding associated with, therapeutic options for)

BMI. *See* Body mass index (BMI)

Body mass index (BMI)

- contraceptive use related to, 649
- epidemiology of obesity and, 648–649
- sexual behavior related to, 649

C

Cesarean section

- sterilization with, 717

CHC. *See* Combined hormonal contraception (CHC)COCs. *See* Combined oral contraceptives (COCs)

Combined hormonal contraception (CHC)

- for adolescents, 636–637
- bleeding profile with, 674–675
- efficacy of, 672–673
- initiation of
 - examination and tests prior to, 665
 - non-oral, 676–677
 - progestogen in
 - VTE risk related to, **683–698**
 - background risks, 687–689
 - introduction, 683–684

- safety of, 673–674
- Combined oral contraceptives (COCs), **669–681**
 - bleeding profile with, 674–675
 - efficacy of, 672–673
 - extended and continuous
 - development of, 671–672
 - flexible and tailored regimens of, 676
 - introduction, 669–670
 - patient acceptability of, 675–676
 - physiology of
 - VTE related to, 686–687
 - regimen types
 - described, 670–671
 - safety of, 673–674
 - terminology related to, 670–671
 - in treatment of menstrual symptoms, 675
- Confidentiality
 - during adolescent reproductive health visit, 633
- Contraception. *See also specific methods*
 - ACA and, 605–608
 - for adolescents
 - providing, **631–645** (*See also Adolescent(s), contraception for*)
 - emergency, **699–712** (*See also Emergency contraception (EC)*)
 - hormonal
 - without prescription
 - women's interest in, 620–621
 - initiation of
 - after EC, 706
 - long-acting reversible
 - in decreasing unplanned pregnancy, **557–567** (*See Long-acting reversible contraception (LARC)*)
 - methods of (*See also specific methods*)
 - initiation of, **659–667** (*See also Contraceptive method initiation*)
 - in obese/overweight women, **647–657** (*See also Obese/overweight women, contraceptive methods for*)
 - postpartum intrauterine
 - immediate, **569–582** (*See also Postpartum intrauterine contraception (PPIUC), immediate*)
 - weight effects of, 653–654
 - in women of different BMIs, 649
- Contraception CHOICE project, 639
- Contraceptive CHOICE project, 563–564
- Contraceptive coverage
 - ACA on, **605–617** (*See also Affordable Care Act (ACA)*)
- Contraceptive coverage mandate
 - of ACA, 607–608
 - compliance with, 609
 - discussion, 613–614
 - legal challenges facing, 611–613
 - limitations and inconsistencies with compliance to, 608–609
 - Medicaid expansion and expanded contraceptive access, 608

Contraceptive (*continued*)

- no-cost contraceptive coverage expansion, 608
- implementation of
 - status of
 - progress and delays, 608–614
- Contraceptive method initiation, **659–667**
 - described, 660–663
 - examination and tests prior to, 664–665
 - follow-up care, 665
 - introduction, 659–660
 - postabortion, 664
 - postpartum, 663
 - in special circumstances, 663–664
- Contraceptive patch
 - in adolescents, 637
- Contraceptive ring
 - in adolescents, 637
 - in obese/overweight women
 - efficacy of, 651
- Copper intrauterine device (Cu-IUD)
 - in adolescents, 634–635
 - described, 703
 - in EU, 703–704
 - mechanism of action of, 703
 - safety of, 703
 - side effects of, 703–704
 - unscheduled bleeding associated with
 - therapeutic options for, 594–596
- Cu-IUD. *See* Copper intrauterine device (Cu-IUD)

D

- Depot medroxyprogesterone acetate (DMPA)
 - in adolescents, 636
 - in obese/overweight women
 - efficacy of, 650
- DMPA. *See* Depot medroxyprogesterone acetate (DMPA)

E

- EC. *See* Emergency contraception (EC)
- Electrocoagulation
 - laparoscopic
 - in female sterilization, 715
- Emergency contraception (EC), **699–712**
 - copper IUD, 703–704
 - increasing access to, 706–707
 - introduction, 699–701
 - LNG-containing EC pill, 705
 - oral EC interactions with other medications, 706
 - oral forms of, 704–705

pregnancy risk with, 701–703

UPA in, 704

when to start contraception after, 706

Yuzpe method, 705–706

ENG implant. *See* Etonogestrel (ENG) implant

Estrogen

for unscheduled bleeding associated with LNG IUD, 598

Etonogestrel (ENG) implant

for adolescents, 634

in obese/overweight women

efficacy of, 650

unscheduled bleeding associated with

therapeutic options for, 598–601

F

Family planning

ACA in, 607

G

Grandfathered plans

contraceptive coverage mandate of ACA and, 608–609

H

Hysteroscopy

microinserts placement via

in transcervical sterilization, 718–719

I

Immediate intrauterine device (IUD) insertion

after surgical abortion, **583–591** (*See also* Intrauterine device (IUD), immediate, after surgical abortion)

Injectable progestins

in obese/overweight women

efficacy of, 650

Insurance

contraception for adolescents through, 638

Intrauterine device(s) (IUDs)

in adolescents

special considerations for, 635

copper (*See* Copper intrauterine device (Cu-IUD))

in obese/overweight women

efficacy of, 649–650

Intrauterine device (IUD) insertion

after first trimester surgical abortion, 585–586

after second trimester surgical abortion, 586–587

immediate

after surgical abortion, **583–591**

Intrauterine (*continued*)

- background of, 583–584
- bleeding patterns, 587–588
- complications of, 588–589
- continuation and expulsion, 584
- follow-up care, 588
- patient experience with, 589
- preprocedure preparation, 584–585
- safety issues, 588–589
- ultrasound guidance in, 587

initiation of

- examination and tests prior to, 664

IUDs. See Intrauterine device(s) (IUDs)

L

Laparoscopy

- in female sterilization, 714–717
 - adverse effects of, 716
 - comparison of techniques, 716
 - electrocoagulation in, 715
 - mechanical occlusion, 715–716
 - tubal sterilization failure after, 716–717

LARC. See Long-acting reversible contraception (LARC)

Legal issues

- ACA-related, 609–610

Levonorgestrel (LNG)-containing emergency contraceptive pill, 705

Levonorgestrel (LNG) intrauterine device (IUD)

- for adolescents, 634
- unscheduled bleeding associated with
 - therapeutic options for, 596–598

LNG IUD. See Levonorgestrel (LNG) intrauterine device (IUD)

Long-acting reversible contraception (LARC)

- for adolescents, 633
- in decreasing unplanned pregnancy, **557–567**
 - barriers to use of, 559–562
 - health care systems issues, 561–562
 - providers issues, 561
 - women's issues, 559–560
 - increased use of, **557–567**
 - in Colorado, 564
 - Contraceptive CHOICE project, 563–564
 - introduction, 557–558
 - in Iowa, 564
 - results of, 562–564
- OTC access to OCs effects on, 624
- unscheduled bleeding associated with
 - therapeutic options for, **593–603**
 - copper IUD, 594–596
 - ENG implant, 598–601
 - introduction, 593–594

LNG IUD, 596–598

vs. short-acting contraceptive methods
efficacy of, 558–559

M

Matrix metalloproteinase (MMP) inhibitors

for unscheduled bleeding associated with ENG implant, 600

MEC. *See* Medical Eligibility Criteria (MEC)

Mechanical occlusion

laparoscopic

in female sterilization, 715–716

Medicaid

ACA in expansion of, 607

contraception for adolescents through, 638–639

Medical Eligibility Criteria (MEC)

in contraceptive use among obese/overweight women, 652

Menstrual symptoms

treatment of

COCs in, 675

MMP inhibitors. *See* Matrix metalloproteinase (MMP) inhibitors

N

Non-oral combined hormonal contraception (CHC), 676–677

Nonsteroidal antiinflammatory drugs (NSAIDs)

for unscheduled bleeding

Cu-IUD-related, 595–596

ENG implant-related, 599–600

LNG IUD-related, 597

NSAIDs. *See* Nonsteroidal antiinflammatory drugs (NSAIDs)

O

Obese/overweight women

contraceptive efficacy in, 649–652

contraceptive methods for, **647–657**

efficacy of, 649–652

introduction, 647–648

pharmacodynamics of, 649–652

pharmacokinetics of, 649–652

risks related to, 652–653

Obesity

defined, 648

epidemiology of, 648–649

prevalence of, 647

OCs. *See* Oral contraceptives (OCs)

Open abdominal sterilization methods

female, 717

Opportunistic salpingectomy, 717–718

Oral contraceptives (OCs)

combined, **669–681** (*See also* Combined oral contraceptives (COCs))

Oral (*continued*)

- in obese/overweight women
 - efficacy of, 650–651

OTC access to, **619–629**

- adolescents use of, 623–624
- areas of concern related to, 623–625
- cost and insurance coverage issues, 623
- effectiveness of, 621–622
- introduction, 619–620
- lack of familiarity with POPs, 625
- lost opportunity to counsel about LARC methods related to, 624
- ongoing use
 - evidence regarding, 622–623
- preventive screening related to, 624
- safety of, 621–622
- support among professional medical and nursing groups, 625–626
- women's interest in, 620–621

OTC access. *See* Over-the-counter (OTC) access

Over-the-counter (OTC) access

- to OCs, **619–629** (*See also* Oral contraceptives (OCs), OTC access to)

Overweight

- defined, 648

P

Pelvic inflammatory disease (PID)

- testing for
 - in adolescents, 635

Perforation

- IUD insertion after surgical abortion and, 588

PID. *see* Pelvic inflammatory disease (PID)

POPs. *See* Progestin-only pills (POPs)

Postabortion contraceptive method initiation, 664

Postpartum contraceptive method initiation, 663

Postpartum intrauterine contraception (PPIUC)

- described, 570
- immediate, **569–582**
 - complications of, 579
 - expulsion rate with, 578–579
 - indications for, 570–571
 - introduction, 569
 - patient evaluation prior to, 579–581
 - placement of, 571–578

PPIUC. *See* Postpartum intrauterine contraception (PPIUC)

Pregnancy

- EC and
 - risks factors for, 701–703
- unplanned

- LARCS in decreasing, **557–567** (*See also* Long-acting reversible contraception (LARC), in decreasing unplanned pregnancy)

Preventive health care

- ACA in, 605–607
- Progestin(s)
 - injectable
 - in obese/overweight women
 - efficacy of, 650
 - third- and fourth-generation
 - VTE risks related to
 - contraceptive ring and patch, 692
 - first pill scare, 691
 - history of, 689–693
 - prospective studies, 692–693
 - second pill scare, 691–692
- Progestin-only contraception
 - in adolescents, 636
- Progestin-only pills (POPs)
 - for adolescents, 636
 - lack of familiarity with
 - OTC access to OCs and, 625
- Progestogen(s)
 - in CHC
 - VTE risk related to, **683–698** (*See also* Combined hormonal contraception (CHC), progestogen in)
 - types of, 684–686

S

- Salpingectomy
 - opportunistic, 717–718
- School-based health centers
 - contraception for adolescents at, 638
- Selective progesterone receptor modulators
 - for unscheduled bleeding associated with LNG IUD, 598
- Sexual behavior
 - discussion about
 - during adolescent reproductive health visit, 633
 - of women of different BMIs, 649
- Sexually transmitted infections (STIs)
 - discussion about
 - during adolescent reproductive health visit, 633
 - screening for
 - before immediate IUD insertion after surgical abortion, 584–585
 - testing for
 - in adolescents, 635
- Sterilization, **713–724**
 - female
 - after cesarean section, 717
 - contraindications to, 720
 - counseling related to, 719–720
 - failure of, 720
 - laparoscopy, 714–717 (*See also* Laparoscopy)
 - open abdominal methods in, 717

Sterilization (*continued*)

- opportunistic salpingectomy, 717–718
- transcervical, 718–719
- tubal
 - failure after laparoscopic sterilization, 716–717
- introduction, 713–714
- male, 720–721
 - costs related to, 721
 - sterilization reversal, 721
 - vasectomy, 721

Sterilization reversal

- male, 721

STIs. *See* Sexually transmitted infections (STIs)

Surgical abortion

- first trimester
 - IUD insertion after, 585–586
- immediate IUD insertion after, **583–591** (*See also* Intrauterine device (IUD) insertion, immediate, after surgical abortion)
- second trimester
 - IUD insertion after, 586–587

T

Thromboembolism

- venous (*See* Venous thromboembolism (VTE))

Title X

- contraception for adolescents through, 638–639

Transcervical sterilization, 718–719

Transdermal patch

- in obese/overweight women
 - efficacy of, 651–652

Tubal sterilization

- failure of
 - after laparoscopic sterilization, 716–717

U

Ulipristal acetate (UPA)

- in EC, 704

Ultrasound

- in IUD placement after surgical abortion, 587

Unplanned pregnancy

- LARC in decreasing, **557–567** (*See also* Long-acting reversible contraception (LARC), in decreasing unplanned pregnancy)
 - in women of different BMI groups, 648–649
- UPA. *See* Ulipristal acetate (UPA)

V

Vaginal ring

- in adolescents, 637

- in obese/overweight women
 - efficacy of, 651

Vasectomy

- costs related to, 721

Venous thromboembolism (VTE)

- COCs physiology and, 686–687

- contraceptive use among obese/overweight women and, 652–653

- progestogen in CHC and, **683–698** (*See also* Combined hormonal contraception (CHC), progestogen in)

VTE. *See* Venous thromboembolism (VTE)

W

Weight

- contraceptive effects on, 653–654

Y

Yuzpe method

- in EC, 705–706